12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
amethasone (20 mg/m 2 I.V. on D1-5, D15-19). All patients except severe
thrombocytopenia received aspirin daily for the prophylaxis of deep
vein thrombosis. Autologous peripheral blood stem cells (PBSC) were
collected after mobilizing with G-CSF with or without cyclophosphamide.
Results. 66 patients (TD regimen: 31 patients, TCD regimen:
35 patients) who received at least 4 cycles or more were evaluated for
response and toxicity. There were 33 males (50%) and 33 females (50%).
The median age of patients was 66 years (range, 39-80 years). The overall
response rate for thalidomide-containing regimens was 84.8%. There
were 13 (41.9%) complete responses and 14 (45.2%) partial responses
for TD regimen and 11 (31.4%) complete responses and 18 (51.4%) partial
responses for TCD regimen, respectively. There was no significant
difference in overall response rate between two treatment groups (TD:
87.1% vs. TCD: 82.8%, p=0.63). However, the progression-free survival
(PFS) was significantly shorter in patients treated with TD regimen than
those treated with TCD regimen (8.6±1.2 ms. vs. 19.4±4.8 ms. p